Reported
Lowest–highest estimate
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Novozymes A/S
XMUN:NZM2
Novozymes A/S
XMUN:NZM2
Price:
59.24
EUR
1.75%
Market Closed
Market Cap:
€16.4B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
N
|
Novozymes A/S
XMUN:NZM2
|
DK |
|
T
|
Takeda Pharmaceutical Co Ltd
DUS:TKD
|
JP |
Wall St Price Targets
NZM2 Price Forecast
Based on 20 analysts
Based on 20 analysts
+16% Upside
from
€59.24
today
Novozymes A/S (NZM2)’s 12-month stock price forecast through September 2027 has a consensus target of €68.44, implying 16% upside. The forecast is based on price targets from 20 Wall Street analysts.
NZM2 Analyst Rating
No ratings yet
No ratings yet
Novozymes A/S Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NZM2's stock price target?
Price Target
68.44
EUR
68.44
EUR
According to Wall Street analysts, the average 1-year price target for NZM2 is 68.44 EUR with a low forecast of 56.11 EUR and a high forecast of 76.09 EUR.
What is the Revenue forecast for Novozymes A/S?
Projected CAGR
-55%
-55%
Over the last 7 years, the compound annual growth rate for Revenue has been 3%. The projected CAGR for the next 2 years is -55%.
What is the Net Income forecast for Novozymes A/S?
Projected CAGR
-56%
-56%
Over the last 7 years, the compound annual growth rate for Net Income has been 0%. The projected CAGR for the next 2 years is -56%.